Diosynth Biotechnology

Diosynth Biotechnology Announces Agreement with Pfizer

Thu, 18 Oct 2007 16:39:15 -0400

Diosynth Biotechnology Announces Supply Agreement Extension with Pfizer for Production of a Recombinant Protein Drug

Diosynth Biotechnology announces agreement with VGX Pharmaceuticals

Wed, 02 May 2007 09:50:00 -0400

Diosynth Biotechnology announced today that it has signed an agreement with VGX Pharmaceuticals for process development activities and cGMP production of clinical trial material for their biological therapeutic drug candidate VGX-100.

Diosynth Biotechnology Announces Agreement with Talecris Biotherapeutics

Mon, 02 Apr 2007 10:50:00 -0400

Diosynth Biotechnology announces agreement with Talecris Biotherapeutics for Process Development and Clinical Production of Recombinant Plasminogen.

Diosynth Biotechnology Announces Extension Agreement with PDL BioPharma

Wed, 07 Feb 2007 10:40:00 -0500

Diosynth Biotechnology signed an extension of its exclusive agreement with PDL BioPharma, Inc. for the commercial manufacture of Retavase®

Diosynth Biotechnology Appoints New President

Fri, 26 Jan 2007 20:00:00 -0500

Jacques van Kimmenaede has been appointed President of Diosynth Biotechnology in RTP, NC, USA. He joins Diosynth Biotechnology from Organon where he held senior executive management positions in manufacturing and global marketing.

Viron Signs Agreement With Diosynth Biotechnology For Clinical Manufacturing Of Vt-111

Tue, 24 Oct 2006 20:00:00 -0400

Viron Therapeutics, Inc. signed an agreement with Diosynth Biotechnology for process development, scale-up, and clinical manufacturing for their lead product candidate.

Diosynth Biotechnology Enters Long-term Commercial Supply Agreement With Dendreon Corporation

Thu, 02 Mar 2006 16:20:00 -0500

Diosynth Biotechnology announced today that it has entered into a long-term commercial supply agreement with Dendreon Corporation (NASDAQ: DNDN) for the manufacture of the recombinant antigen component of PROVENGE? (sipuleucel-T), Dendreon’s investigational active cellular immunotherapy for prostate cancer.

Vernalis Signs Agreement With Diosynth Biotechnology For Phase Iii Manufacture Of V10153

Thu, 22 Sep 2005 20:00:00 -0400

Vernalis Plc has signed a contract with Diosynth Biotechnology for process development, scale-up and manufacturing of V10153 for Phase III clinical trials.

Amendment To Validation And Manufacturing Agreement With Neopharm, Inc. For Il13-pe38qqr

Wed, 21 Sep 2005 20:10:00 -0400

Diosynth Biotechnology today announced that it has agreed to an amendment of the current agreement it has with NeoPharm, Inc. (Nasdaq: NEOL) to provide for Diosynth's performing validation and conformance lot manufacturing of NeoPharm's cintredekin besudotox (IL13-PE38QQR) drug candidate in the event NeoPharm is able to move forward with a Biologic License Application (BLA) at the conclusion of its pivotal Phase III PRECISE trial for cintredekin besudotox.